The increasing prevalence of chronic and infectious diseases is significantly driving the global biopharmaceutical market revenue. Additionally, the rising number of clinical trials is a notable trend contributing to industry growth.
Given the industry’s bright prospects, it could be wise to invest in fundamentally strong biotech stocks, such as Alnylam Pharmaceuticals, Inc. (ALNY), Illumina, Inc. (ILMN), and Gilead Sciences, Inc. (GILD) for long-term growth.
